Picture of Seer logo

SEER — Seer News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousSmall CapNeutral

Seer Q2 revenue falls 23% as funding slows

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
Overview
    * U.S. proteomics technology provider's Q2 revenue fell 23% yr/yr due to macroeconomic headwinds
    * Net loss for Q2 narrowed as operating expenses declined 19% yr/yr
    * Company repurchased about 200,000 shares under its share repurchase program

Outlook
    * Seer maintains 2026 revenue guidance of $16 mln to $18 mln

Result Drivers
    * MACROECONOMIC HEADWINDS - Co said lower product and service revenue was primarily due to continued macroeconomic headwinds in academic and government funding
    * LONGER SALES CYCLES - Co cited continued elongation of sales cycles in some commercial accounts related to extended customer evaluations
    * LOWER OPERATING EXPENSES - Operating expenses fell mainly due to a decrease in employee compensation expenses, including stock-based compensation

Company press release:  ID:nGNX7MDKMb 
Key Details
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
 Q2                  $3.10      
 Revenue             mln       
 Q2 Loss             $0.31      
 Per                           
 Share                         
 Q2 Net              $16.90     
 Loss                mln       
 Q2 Gross            49%        
 Margin                        
 Q2 Gross            $1.51      
 Profit              mln       
 Q2                  $18.35     
 Operatin            mln       
 g                             
 Expenses                      
 Analyst Coverage
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the office equipment peer group is "buy"
    * Wall Street's median 12-month price target for Seer, Inc. is $4.00, about 85.2% above its August 10 closing price of $2.16

Reuters Recommended Reads
    * Aug 10 - Bionano Genomics Q2 revenue rises on increased clinical adoption
    * Aug 11 - 908 Devices Q2 revenue beats on increased VipIR sales
    * Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Seer

See all news